HedgeChatter

  • Home /
  • Tag Archives

ARIA

PropThink: ARIAD Building an Oncology Business Around Discovery, Development, and Commercialization

[ACN Newswire] – In an exclusive PropThink interview with ARIAD Pharmaceuticals (NASDAQ:ARIA), CEO Harvey J. Berger discusses the company’s lead product, ponatinib, a potential treatment for intolerant Chronic Myeloid … moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboard […]

October 4, 2012 Bystocknews , Comments Off on PropThink: ARIAD Building an Oncology Business Around Discovery, Development, and Commercialization read more

PropThink: Phase I/II Data On New Candidate Supports Higher Valuation For ARIA

[ACN Newswire] – By David MoskowitzWith Wall Street Analyst price targets on Ariad Pharmaceuticals (NASDAQ:ARIA) averaging $24.75 through this morning, new data for an early-stage pipeline candidate is causing price targets … moreView todays social media effects on ARIAView the latest stocks trending across Twitter. Click to view dashboard […]

October 1, 2012 Bystocknews , Comments Off on PropThink: Phase I/II Data On New Candidate Supports Higher Valuation For ARIA read more